Showing 7241-7250 of 10214 results for "".
- Envy Medical and Libbs Farmaceutical Plan Strategic Marketing, Sales and Distribution Agreement For Brazilhttps://practicaldermatology.com/news/20140723-envy_medical_and_libbs_farmaceutical_plan_strategic_marketing_sales_and_distribution_agreement_for_brazil/2459159/Envy Medical and Libbs Farmaceutical made an agreement to manufacture, market and sell Envy's proprietary Lumixyl® Brightening Creme throughout the country of Brazil. This represents significant agreement with Libbs, a leader in the sales and supply of pharmaceutical products, it also rep
- Innocutis Introduces Cold Sore Dissolvable Tablet to North American Markethttps://practicaldermatology.com/news/20140722-innocutis_introduces_cold_sore_dissolvable_tablet_to_north_american_market/2459160/Innocutis recently introduced Sitavig ®(ACYCLOVIR) 50mg Buccal Tablet to North American markets for the treatment of herpes labialis. Sitavig uses a proprietary delivery technology which consists of a tasteless and odorless tablet that sticks to the gum above the incisor tooth on the side of the lip
- Study: Dermatologists Preferred for Skin Cancer Evaluation and Treatmenthttps://practicaldermatology.com/news/20140722-study_dermatologists_preferred_for_skin_cancer_evaluation_and_treatment/2459161/Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey, respondents were asked their choice for evaluating a worrisome lesion on the face and for remov
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz
- New Patient Education Service from Vivacare Helps Medical Professionals Deliver Health Education at the Point of Carehttps://practicaldermatology.com/news/20140716-new_patient_education_service_from_vivacare_helps_medical_professionals_deliver_health_education_at_the_point_of_care/2459166/Vivacare, a leading provider of patient education services for physicians, today announced a major upgrade to its free, web-based service and the opportunity for physician assistants, nurse practitioners and other medical professionals to enroll. In just minutes, physicians and other medical pr
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scor
- MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind Systemhttps://practicaldermatology.com/news/20140715-mela_sciences_begins_insurance_reimbursement_process_with_application_for_new_cpt_code_for_the_melafind_system/2459170/MELA Sciences, Inc. (Nasdaq:MELA), announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection o
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife
- Advanced Dermatology & Cosmetic Surgery (ADCS Clinics) Acquires The Grekin Skin Institutehttps://practicaldermatology.com/news/20140714-advanced_dermatology__cosmetic_surgery_adcs_clinics_acquires_the_grekin_skin_institute/2459172/ADCS Clinics ("ADCS") announced it has completed the acquisition of The Grekin Skin Institute in Southfield, Michigan, a dermatology practice founded by Dr. Steven Grekin.
- Aclaris Therapeutics Announces Positive Results from Phase II study of Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/20140702-aclaris_therapeutics_announces_positive_results_from_phase_ii_study_of_seborrheic_keratosis_treatment/2459181/Aclaris Therapeutics, Inc. announced positive results from a Phase II clinical trial of the its lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK). The double-bl